Customer ServiceContact usNews

News

    CryoCath named to Deloitte’s Technology Fast 500

    Montreal, Quebec, Canada - November 14, 2006 - CryoCath Technologies (TSX:CYT), the global leader in cryotherapy products to treat cardiovascular disease, has been named to Deloitte's prestigious Technology Fast 500 Program. This is a ranking of the fastest growing technology, media, telecommunications and life sciences companies by Deloitte & Touche USA LLP, one of the nation’s leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2001–2005. CryoCath was ranked 69th overall on the list.

    “From a standing start in 2001, CryoCath today has five core products routinely used around the world by both electrophysiologists and cardiac thoracic surgeons in more than 800 centers,” said Henri Vienneau, CryoCath’s Interim CEO and Chairman of the Board of Directors. “With more than 200 employees, we are poised to augment this commercial momentum as we currently launch our latest proprietary catheter, Arctic Frontâ to treat Atrial Fibrillation, across Europe.”

    To qualify for the Technology Fast 500, companies must have had operating revenues of at least $75,000 in 2001 and $5,000,000 in 2005, be headquartered in North America, and own proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues, or devotes a significant proportion of revenues to the research and development of technology.

    For more information on Deloitte’s Technology Fast 50 or Technology Fast 500 programs, visit www.fast500.com.

    About Medtronic CryoCath

    CryoCath - www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiovascular disease. With a priority focus on providing physicians with a complete solution of catheter and surgical products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.

    This press release includes “forward-looking statements” that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath’s annual report available at www.sedar.com under the heading Risks and Uncertainties in the Management’s Discussion and Analysis section.

    For further information, please contact:

    Mike Polonsky
    Phone: (416) 815-0700 ext. 231
    E-mail: mpolonsky@equicomgroup.com

    Mike Polonsky
    Phone: (416) 815-0700 ext. 231
    E-mail: mpolonsky@equicomgroup.com